Biogen Inc. looked for a broader label in connection with potential approval of the spinal muscular atrophy (SMA) candidate, nusinersen, after reporting with Ionis Pharmaceuticals Inc. that the phase III CHERISH trial in children with later-onset disease met the primary endpoint at interim analysis and was stopped early.